Previous close | 51.43 |
Open | 52.13 |
Bid | 57.00 x 800 |
Ask | 57.05 x 1800 |
Day's range | 50.88 - 57.55 |
52-week range | 34.88 - 277.80 |
Volume | |
Avg. volume | 6,201,855 |
Market cap | 4.321B |
Beta (5Y monthly) | 1.33 |
PE ratio (TTM) | N/A |
EPS (TTM) | -14.95 |
Earnings date | 28 Feb 2022 - 04 Mar 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 183.40 |
Indeed, the S&P 500 is in bear market territory, defined as a 20% (or more) drop from its most recent high. Take biotech company Novavax (NASDAQ: NVAX). While the broader market sell-off hasn't helped Novavax, the company has encountered its own issues, too.
In the latest trading session, Novavax (NVAX) closed at $51.43, marking a -0.81% move from the previous day.
The FDA is asking COVID-19 vaccine makers to test and produce boosters that target both the original and new BA.4/BA.5 strains of the virus by fall.